Neurocrine Biosciences (NBIX) Raw Materials (2018 - 2025)

Neurocrine Biosciences (NBIX) has reported Raw Materials for 8 consecutive years, with $31.9 million the latest figure, recorded in Q1 2025.

• For the quarter ending Q1 2025, Raw Materials rose 76.24% year-over-year to $31.9 million; the trailing twelve-month figure through Mar 2025 stood at $31.9 million (up 76.24% YoY), and the FY2024 full-year result was $33.7 million, up 56.74% from the prior year.
• Raw Materials retreated to $31.9 million in Q1 2025 per NBIX's latest filing, from $33.7 million in the prior quarter.
• Across five years, Raw Materials topped out at $33.7 million in Q4 2024 and bottomed at $11.2 million in Q4 2021.
• Historically, Raw Materials has averaged $21.7 million across 5 years, with a median of $21.4 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Raw Materials slumped 32.53% in 2021, then jumped 79.17% in 2023.
• Over 5 years, Raw Materials stood at $11.2 million in 2021, then gained by 7.14% to $12.0 million in 2022, then surged by 79.17% to $21.5 million in 2023, then jumped by 56.74% to $33.7 million in 2024, then declined by 5.34% to $31.9 million in 2025.
• According to Business Quant data, Raw Materials over the past three periods registered $31.9 million, $33.7 million, and $23.7 million for Q1 2025, Q4 2024, and Q3 2024 respectively.